BAP1 mutations were associated with worse cancer-specific survival (CSS) in both cohorts of the Memorial Sloan-Kettering Cancer Center (p = 0.002; HR 7.71; 95% confidence interval (CI) 2.08–28.6) and TCGA (p = 0.002; HR 2.21; 95% CI 1.35–3.63) [8,27]. The gene discussed is BAP1; the disease is cancer.